Phase III data for semaglutide as an adjunct to intensive behavioural therapy for weight loss in adults with obesity or overweight

In the STEP 3 study (n=611 with obesity or overweight), once weekly subcutaneous semaglutide 2.4mg was associated with a greater mean reduction in body weight of -16% versus -5.7% with placebo at week 68 (estimated treatment difference: -10.3 [95% CI -12.0, -8.6]; p<0.0001).

SPS commentary:

The other primary endpoint of the study was the proportion of participants who achieved greater than or equal to 5% weight loss, from baseline to the end of treatment; this was also greater in the semaglutide group (87% v 48%; significance nor reported).

Semaglutide is a GLP-1 analogue, licensed in the UK for the treatment of type 2 diabetes mellitus. It is currently being investigated as a potential treatment for obesity. The STEP Phase III programme consists of four studies, and has enrolled approximately 45,000 adults with overweight or obesity. 

Biospace Inc.